KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.

Jamile Shammo, Peter Hillmen, Peter Blandino, Vijay Abilash, David J Kuter

Int J Mol Sci 26(20) 10019

PMID41155315
PMCIDPMC12564155
DOI10.3390/ijms262010019
发表日期2025-10-29
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:研究设计图。
摘要

摘要

Complement factor 5 (C5) inhibitors for paroxysmal nocturnal hemoglobinuria (PNH) may cause iron overload due to residual intravascular hemolysis (IVH) and emergent extravascular hemolysis (EVH). In PEGASUS (phase 3; NCT03500549), adults with PNH with residual anemia (hemoglobin concentration < 10.5 g/dL) after ≥3 months of eculizumab received eculizumab and pegcetacoplan for 4 weeks and were then randomized (1:1) to eculizumab or pegcetacoplan monotherapy for 16 weeks; in the following 32-week, open-label period, patients either continued pegcetacoplan or switched from eculizumab to pegcetacoplan. This post hoc analysis reports PEGASUS transfusion-related data and iron-related biomarkers to evaluate pegcetacoplan's effects on iron regulation. Of 80 patients randomized in PEGASUS, 27 (33.8%) had baseline iron overload (serum transferrin saturation ≥ 50%). Iron overload resolved within 52 weeks of pegcetacoplan treatment in 16 of 22 patients (72.7%) with baseline and postbaseline data; 10 experienced resolution after 20 weeks. With pegcetacoplan, transfusion numbers decreased for patients with and without iron overload, hepcidin concentrations increased, and absolute reticulocyte counts (ARCs) decreased to normal range. Mean ferritin concentrations were above normal throughout the study, regardless of iron overload status. Pegcetacoplan improves iron overload-related biomarkers, including increased hepcidin concentrations and decreased ARCs, by blocking IVH and EVH and preventing anemia.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Reduction in transferrin saturation after up to 52 weeks of pegcetacoplan treatment for PNH. PNH, paroxysmal nocturnal hemoglobinuria. Baseline iron overload was defined as a transferrin saturation ≥ 50% at baseline. Resolution of iron overload was defined as a transferrin saturation < 50% after pegcetacoplan treatment. Only patients with evaluable baseline iron overload were included.
非 KM Figure
Figure 2Figure 2 Concentrations of ( a ) ferritin and ( b ) hepcidin in eculizumab-experienced patients with PNH before and after pegcetacoplan treatment, by baseline iron overload status. PNH, paroxysmal nocturnal hemoglobinuria; ULN, upper limit of normal. Baseline iron overload was defined as a transferrin saturation ≥ 50% at baseline. Only patients with available laboratory values at all timepoints were included in the analysis.
非 KM Figure
Figure 3Figure 3 Mean ARCs before and after pegcetacoplan treatment in eculizumab-experienced patients with PNH and baseline iron overload ( n = 27). ARC, absolute reticulocyte count; LLN, lower limit of normal; PNH, paroxysmal nocturnal hemoglobinuria; ULN, upper limit of normal. Baseline iron overload was defined as a transferrin saturation ≥ 50% at baseline.
非 KM Figure
Figure 4Figure 4 Potential effects of complement C5 inhibitors for PNH on iron regulation. ARC, absolute reticulocyte count; C5, complement factor 5; ECU, eculizumab; EPO, erythropoietin; PNH, paroxysmal nocturnal hemoglobinuria; TSAT, transfusion saturation. Red text indicates iron status markers assessed in the current analysis.
非 KM Figure
Figure 5Figure 5 Study design of the PEGASUS trial and the iron parameters analysis. ECU, eculizumab; PEG, pegcetacoplan.
非 KM Figure